Choi Eunice Yun Kwan, Lim Hoong Sern
Royal Stoke University Hospital, University Hospitals of North Midlands NHS Foundation Trust, Stoke-On-Trent, UK.
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Br J Hosp Med (Lond). 2024 Dec 30;85(12):1-17. doi: 10.12968/hmed.2024.0396. Epub 2024 Dec 23.
Cardiogenic shock (CS) is associated with significant mortality. Advances in pharmacological therapies and mechanical circulatory support (MCS) devices have markedly improved the therapeutic approach to CS, though treatment efficacy and safety vary. The recent DanGer shock trial showed a significant reduction in 6-month mortality for CS patients due to acute myocardial infarction. Future randomised trials should evaluate a phenotype-guided pharmaco-MCS approach to the management of CS. This paper summarises contemporary pharmacological and MCS treatments for patients with CS.
心源性休克（CS）与显著的死亡率相关。尽管治疗效果和安全性各不相同，但药物治疗和机械循环支持（MCS）设备的进展显著改善了CS的治疗方法。最近的DanGer休克试验显示，急性心肌梗死所致CS患者的6个月死亡率显著降低。未来的随机试验应评估一种基于表型指导的药物-MCS方法来管理CS。本文总结了CS患者的当代药物治疗和MCS治疗方法。
